Stocks · News reference
Kymera Therapeutics, Inc. announced it will report its third quarter 2026 financial results on October 29, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Kymera Therapeutics, Inc. announced it will report Phase 1 clinical trial results for its oral IRF5 degrader, KT-579, on October 29, 2026, in conjunction with its third-quarter 2026 financial results.
Analysts initiate coverage: Outperform on American Express and Kymera, Overweight on Kratos, Hold on IBM and Neutral on Duos.